Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN).

SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. For cancer patients suffering from neuropathy as a side effect of chemotherapy, SP163M offers a critically needed solution. The development of neuropathy often necessitates reducing planned chemotherapy regimens, which may affect cancer outcomes. Preventative therapy could be lifesaving for these patients.

As part of this strategic alliance, HekaBio will spearhead the commercialization of SP163M in critical markets, including Japan, Korea, Taiwan, Australia, ASEAN, the Middle East (excluding Israel), and North Africa. This collaboration integrates Serpin Pharma’s prowess in peptide therapeutics with HekaBio’s strong presence in the Asian and Australian markets. HekaBio’s strategic investment in Serpin Pharma, along with milestone and royalty payments, underscores the mutual commitment to the success of this innovative therapy.

Dr. Cohava Gelber, Founder, Executive Chairperson, and CEO of Serpin Pharma, expressed enthusiasm about the collaboration: “We are thrilled to partner with HekaBio to bring this revolutionary therapy to cancer patients. SP163M can potentially significantly improve the quality of life for those undergoing chemotherapy.”

Rob Claar, the CEO of HekaBio, stated: “Our collaboration with Serpin Pharma is inspiring. By combining our complementary capabilities, we aim to deliver a game-changing treatment option for cancer patients suffering from CIPN.”

This partnership marks a significant step towards addressing the unmet medical needs for effective CIPN treatments. As the companies advance their development and commercialization plans, cancer patients in the specified regions may soon have access to this innovative therapy.

Governor Spanberger Announces Expansion of Paid Internship Opportunities with Virginia Businesses

Governor Abigail Spanberger today launched InternshipsVA, a new statewide program to help Virginia employers design and launch high-quality, paid internships for higher education students in Virginia. The Commonwealth has committed $14.5 million each year to support this program. The Governor was joined by leaders of the Virginia Chamber of Commerce, the Virginia Economic Development Partnership …

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by …

02/02/2026

Accorto Regulatory Solutions Launches Dedicated Quality & Compliance Division

Accorto Regulatory Solutions, LLC (Accorto), a U.S.-based regulatory advisory firm, announced the launch of its dedicated Quality & Compliance Division, expanding the firm’s ability to deliver integrated regulatory and compliance support to organizations involved in the development of FDA-regulated products. The new division formalizes and expands Accorto’s compliance and GxP services in response to growing …

News